The artificial tears on the basis hyaluronic acid is primary importance today in dry eye syndrome (DES) treatment. In recent years, they have been supplemented Optinol® Express Moisture (0.21 %) and Optinol® Deep Moisture (0.4 %) differing concentrations of sodium hyaluronate and viscosity. The study is devoted to assessing the effectiveness of these drugs in the treatment of patients with dry eye syndrome (DES) of various etiology and severities.There were 73 volunteers with DES of various etiology: 21 — Sjogren’s syndrome, 24 — meibomian blepharitis, and 28 — perimenopause in the study. All patients were divided into 2 groups: 36 patients of the first group received instillations into conjunctival cavity of the Optinol® Express Moisture (0.21 %) and 37 patients of the second group — Optinol® Deep moistening (0.4 %).Starting from the first days of therapy, all patients had a decrease in the severity of subjective signs of DES, estimated by the value of the ocular surface disease index (OSDI). At the same time, tendency to stop of the degenerative changes in the epithelium of the ocular surface was established. It is characterized by a decrease in the degree of staining. The increasement of the tear film stability and an index of the tear meniscus was found in all patients. The dynamics of the controlled parameters increased, as the instillation of the drugs took place and by the 30th day of therapy. There were significant differences from the baseline values. At the same time, the Optinol® Express Moisture (0.21 %) was more effective (mainly in terms of subjective discomfort and the severity of degenerative changes in the epithelium of the ocular surface) in patients with mild and extremely severe form of the xerosis process.The drug Optinol® Deep Moisture (0.4 %) was more effective in patients with xerosis of moderate severity and severe by the same parameters. In the course of research, we have not observed any side effects of both drugs. It allows us to recommend the drugs Optinol® Express Moisture (0.21 %) and Optinol® Deep Moisture (0.4 %) to widespread clinical use in treating patients with DES of various etiology.

Ocular targeted drug delivery is one of the most challenging tasks for pharmaceutical researchers and practical ophthalmologists. The possibilities of drug delivery to the eye are naturally determined by the anatomical structure of the eye and its physiological properties, which restrict the period when therapeutically required drug concentration could be maintained. Combined drug delivery schemes may, potentially, improve the patient’s acceptance of treatment, reduce side effects, increase efficacy, and eventually preserve vision.

The aim of the study was to evaluate the effectiveness of the preparations Optinol® Express Moisture (0.21 %) and Optinol® Deep Moisture (0.4 %) in the treatment of children with dry eye syndrome (DES) and to determine the indications for prescribing these drugs for various etiologies and clinical course of the disease.Patients and methods. The study involved 56 children aged 4–17 years with DES, which were divided into 3 groups, depending on its pathogenetic type. The first consisted of 24 children with DES, which developed on the basis of chronic blepharitis, the second — 12 children with neuroparalytic keratitis, and the third — 18 children with chronic uveitis, in whom DES was caused by prolonged instillations of eye drops with benzalkonium chloride. Each group was divided into 2 more equal subgroups, the first of which was prescribed the drug Optinol® Express Moisture, and the second — Optinol® Deep Moisture with a frequency of 4 times a day.Results. In all children, from the very first days of instillation of the studied drugs, a decrease in the severity of subjective signs of DES (OSDI) was noted, as well as a gradual decrease in the degree of xerotic changes in the ocular surface (severity of its staining with vital dyes) and an increase in the stability of the tear film (M.Norn). At the same time, the positive dynamics of the controlled parameters increased with the continuation of therapy, reaching a maximum by the 30th day of treatment. Moreover, the effectiveness of therapy depended on the severity of xerosis of the ocular surface: it was maximal in children with mild, and minimal in children with an extremely severe form of xerosis (with neuroparalytic keratitis). Moreover, the drug Optinol® Express Moisture was more effective in the treatment of children with mild and extremely severe forms of DES, and Optinol® Deep Moisture — with moderate and severe xerosis.Conclusion. The preparations Optinol® Express Moisture and Optinol® Deep Moisturization are effective in the treatment of children with DES, which has developed on the basis of pathology of the ocular surface of neurotrophic and artifact genesis, as well as increased volatility of the precorneal tear film against the background of chronic blepharitis.

Актуальность. Изменения угла передней камеры (УПК) играют ведущую роль в этиопатогенезе как врожденной глаукомы, так и глаукомы на фоне ретинопатии недоношенных (РН). Исследование параметров УПК у таких детей при помощи современных методов визуализации является актуальной задачей современной офтальмологии. Цель. Исследование УПК у детей с врожденной глаукомой и глаукомой, протекающей на фоне РН различных стадий, при помощи оптического когерентного томографа. Материал и методы. Обследованы 28 детей (33 глаза), среди которых 5 (7 глаз) – с врожденной глаукомой и 23 (26) – с глаукомой на фоне рубцового периода РН. РН II стадии была выявлена у 5 детей (7 глаз), III стадии – у 11 (11) и 7 детей (8 глаз) наблюдались с РН IVа стадии. Всем детям проводили исследование УПК с помощью оптического когерентного томографа Carl Zeiss Cirrus HD-OCT 5000 с использованием внешней линзы передней камеры. Оценивали ширину УПК и дистанцию трабекула-радужка (ДТР). Результаты. В группе детей с врожденной глаукомой средняя ширина УПК составила 47,29±11,93°, средняя ДТР – 607,14±117,57 мкм. У детей с глаукомой на фоне РН данные параметры составили, в среднем, 41,04±10,64° и 470,77±139,11 мкм соответственно. При этом наименьшие значения ширины УПК и ДТР были выявлены в группе детей с IVа стадией РН и составили 30,25±12,33° и 350±105,02 мкм. Выводы. В группе детей с глаукомой на фоне ретинопатии недоношенных отмечается уменьшение ширины УПК и дистанции трабекула-радужка по сравнению с детьми с врожденной глаукомой. Данная тенденция наиболее выражена в группе детей с IVа стадией РН, что, вероятно, обусловлено деформацией УПК в ходе выраженного экстраретинального пролиферативного процесса.